Skip to main content

Table 2 Causative pathogens of all nosocomial infection episodes in cancer patients

From: Establishment and validation of a nomogram to predict the in-hospital death risk of nosocomial infections in cancer patients

Causative organisms

Whole cohort (n = 1008)

Training cohort (n = 708)

Validation cohort (n = 300)

Pb

Survival (n = 610)

Death (n = 98)

Pa

Gram-negative bacteria

388 (38.5)

229 (37.5)

31 (31.6)

0.260

128 (42.7)

0.076

 Escherichia coli

135 (13.4)

71 (11.6)

10 (10.2)

0.679

54 (18.0)

0.005*

 Klebsiella pneumoniae

65 (6.4)

38 (6.2)

11 (11.2)

0.071

16 (5.3)

0.348

 Pseudomonas aeruginosa

86 (8.5)

54 (8.9)

4 (4.1)

0.110

28 (9.3)

0.553

 Enterobacter spp.

34 (3.4)

21 (3.4)

2 (2.0)

0.675

11 (3.7)

0.737

 Klebsiella oxytoca

4 (0.4)

3 (0.5)

0 (0.0)

1.000

1 (0.3)

1.000

 Proteus mirabilis

13 (1.3)

8 (1.3)

2 (2.0)

0.915

3 (1.0)

0.822

 Salmonella enterica serovar

2 (0.2)

1 (0.2)

0 (0.0)

1.000

1 (0.3)

0.507

 Haemophilus spp

42 (4.2)

28 (4.6)

2 (2.0)

0.372

12 (4.0)

0.863

 Serratia

7 (0.7)

5 (0.8)

0 (0.0)

1.000

2 (0.7)

1.000

Gram-positive bacteria

143 (14.2)

87 (14.3)

14 (14.3)

0.995

42 (14.0)

0.912

 Staphylococcus aureus

71 (7.0)

40 (6.6)

7 (7.1)

0.829

24 (8.0)

0.440

 MRSA

7 (0.7)

4 (0.7)

2 (2.0)

0.196

1 (0.3)

0.681

 Streptococcus pneumoniae

37 (3.7)

21 (3.4)

3 (3.1)

1.000

13 (4.3)

0.466

 Coagulase-negative staphylococci

15 (1.5)

13 (2.1)

1 (1.0)

0.732

1 (0.3)

0.092

 Streptococcus anginosus

13 (1.3)

9 (1.5)

1 (1.0)

1.000

3 (1.0)

0.822

Enterococcus

26 (2.6)

15 (2.5)

6 (6.1)

0.096

5 (1.7)

0.234

 E. faecalis

12 (1.2)

7 (1.1)

3 (3.1)

0.303

2 (0.7)

0.496

 E. faecium

10 (1.0)

5 (0.8)

2 (2.0)

0.251

3 (1.0)

1.000

 Enterococcus spp

4 (0.4)

3 (0.5)

1 (1.0)

0.450

0 (0.0)

0.324

Anaerobes

6 (0.6)

5 (0.8)

0 (0.0)

1.000

1 (0.3)

0.676

Fungi

115 (11.4)

60 (9.8)

21 (21.4)

0.001

34 (11.3)

0.961

 Candida albicans

79 (7.8)

44 (7.2)

13 (13.3)

0.041*

22 (7.3)

0.698

 Candida spp.

14 (1.4)

7 (1.1)

2 (2.0)

0.805

5 (1.7)

0.844

 Aspergillus flavus

22 (2.2)

9 (1.5)

6 (6.1)

0.010*

7 (2.3)

0.831

MDRGNB

250 (24.8)

162 (26.6)

23 (23.5)

0.518

65 (21.7)

0.134

 ESBL-producing  Escherichia coli

156 (15.5)

102 (16.7)

17 (17.3)

0.878

37 (12.3)

0.073

 MDR Pseudomonas aeruginosa

13 (1.3)

10 (1.6)

0 (0.0)

0.415

3 (1.0)

0.822

 Acinetobacter baumannii

30 (3.0)

18 (3.0)

1 (1.0)

0.447

11 (3.7)

0.401

 Stenotrophomonas maltophilia

16 (1.6)

8 (1.3)

3 (3.1)

0.390

5 (1.7)

1.000

 ESBL-producing Klebsiella pneumoniae

31 (3.1)

20 (3.3)

2 (2.0)

0.732

9 (3.0)

0.928

 Carbapenem-resistant Enterobacteriaceae

4 (0.4)

4 (0.7)

0 (0.0)

1.000

0 (0.0)

0.324

Polymicrobial

80 (7.9)

52 (8.5)

3 (3.1)

0.061

25 (8.3)

0.762

  1. MRSA, Methicillin-resistant S. aureus; MDRGNB, multidrug-resistant gram-negative bacilli; ESBL, extended-spectrum β-lactamase; MDR: multidrug-resistant
  2. aP value for univariate analysis of the training cohort
  3. bP value for clinical characteristics analysis between the training cohort and validation cohort
  4. *Indicates statistical significance